Opinion|Videos|December 15, 2023
KEYNOTE-522: Event-Free Survival With Neoadjuvant and Adjuvant Pembrolizumab in TNBC
Medical oncologists discuss recent data from KEYNOTE-522 looking at event-free survival with neoadjuvant and adjuvant pembrolizumab in triple-negative breast cancer.
Advertisement
Episodes in this series
Advertisement
Related to this article
Giredestrant plus everolimus reduced the risk of progression or death by 44% in the ITT population and 62% in ESR1-mutated disease in phase 3 evERA data published in NEJM.
Elinzanetant, already approved for menopause-related VMS, is being considered to address hot flashes associated with adjuvant breast cancer endocrine therapy.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Behind the FDA Approval: Rusfertide Redefines the Polycythemia Vera Paradigm
2
FDA Grants Fast Track Designation to TRE-515 for KRAS G12C NSCLC
3
Pirtobrutinib Gains FDA Approval for Frontline CLL/SLL in Select Patients
4
Extended Survival Raises New Questions on Imaging and Treatment Intensification in ROS1+ NSCLC
5